Effect of Peruvosid (CD412) on excitability and functional refractory period of atrial and ventricular tissues in cardiomyopathy caused by Trypanosoma cruzi.
Attempts were made to produce myocarditis by Trypanosoma cruzi inoculation in healthy dog puppies 6 to 8 weeks old. Significant electrocardiographic abnormalities were produced, coinciding with interstitial inflammatory processes in the cardiac tissue and with degenerative changes in the myocardial fibres. In puppies showing these changes, profound changes in the excitability and the functional refractory period of the atrial and ventricular muscular tissue were observed. The administration of Peruvosid in doses of 0.0240 to 0.0647 mg./kg. tended to diminish the excitability, previously increased by the inflammatory process, at the same time increasing the functional refractory period duration which had previously been shortened. The fact that Peruvosid corrects these fundamental factors in the genesis of cardiac arrhythmias suggests that the drug may be useful in the treatment of cardiac insufficiency produced by Chagas' myocardiopathy, in which arrhythmias are one of the basic characteristics.
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy; D002301:Cardiac Glycosides / Q000494:pharmacology*; D014355:Chagas Disease / Q000150:complications*; D004285:Dogs; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects*; D009205:Myocarditis / Q000209:etiology*; D009206:Myocardium / Q000473:pathology
D002301:Cardiac Glycosides